Age-Stratified Risk of Carboplatin-Induced Nausea and Vomiting in Lung Cancer Patients.

IF 2.5 3区医学 Q3 ONCOLOGY Oncology Pub Date : 2025-03-10 DOI:10.1159/000544875

Koki Hashimoto, Takashi Yokokawa, Yuma Nonomiya, Naoki Shibata, Azusa Soejima, Kazuo Kobayashi, Yutaro Mae, Akiko Hasegawa, Takeshi Aoyama, Yoshikazu Tateai, Shuhei Ban, Kotono Nigata, Ryusei Abe, Kazuyoshi Kawakami, Hisanori Shimizu, Ryo Ariyasu, Noriko Yanagitani, Kaname Hasegawa, Masakazu Yamaguchi, Kenichi Suzuki

{"title":"Age-Stratified Risk of Carboplatin-Induced Nausea and Vomiting in Lung Cancer Patients.","authors":"Koki Hashimoto, Takashi Yokokawa, Yuma Nonomiya, Naoki Shibata, Azusa Soejima, Kazuo Kobayashi, Yutaro Mae, Akiko Hasegawa, Takeshi Aoyama, Yoshikazu Tateai, Shuhei Ban, Kotono Nigata, Ryusei Abe, Kazuyoshi Kawakami, Hisanori Shimizu, Ryo Ariyasu, Noriko Yanagitani, Kaname Hasegawa, Masakazu Yamaguchi, Kenichi Suzuki","doi":"10.1159/000544875","DOIUrl":null,"url":null,"abstract":"Introduction: Age has been reported as a risk factor for chemotherapy-induced nausea and vomiting. However, few reports have described risk factors for nausea and vomiting with carboplatin (CBDCA). This study investigated whether the incidence of CBDCA-induced nausea and vomiting differs with age, using 70 years as the cutoff.Methods: Patients who underwent CBDCA for lung cancer at the Cancer Institute Hospital of Japanese Foundation for Cancer Research between November 2020 and October 2023 were included in this retrospective study. The age cut-off was set at 70 years, with complete response (CR; no vomiting/retching and no rescue medication) rate during the observation period as the endpoint.Results: A total of 198 patients were included in the analysis, of whom 114 (57.6%) were ≥70 years old, with a CR rate of 36.9% for patients <70 years old and 61.4% for those ≥70 years old (p = 0.001). In univariate analysis, age <70 years old, female sex, no drinking history, no smoking history and CBDCA dose were associated with non-CR. In multivariate analysis, age <70 years old, no drinking history and CBDCA dose were associated with non-CR.Conclusion: Age <70 years old, no drinking history and CBDCA dose were identified as risk factors for CBDCA-induced nausea and vomiting.","PeriodicalId":19497,"journal":{"name":"Oncology","volume":" ","pages":"1-23"},"PeriodicalIF":2.5000,"publicationDate":"2025-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000544875","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Age has been reported as a risk factor for chemotherapy-induced nausea and vomiting. However, few reports have described risk factors for nausea and vomiting with carboplatin (CBDCA). This study investigated whether the incidence of CBDCA-induced nausea and vomiting differs with age, using 70 years as the cutoff.

Methods: Patients who underwent CBDCA for lung cancer at the Cancer Institute Hospital of Japanese Foundation for Cancer Research between November 2020 and October 2023 were included in this retrospective study. The age cut-off was set at 70 years, with complete response (CR; no vomiting/retching and no rescue medication) rate during the observation period as the endpoint.

Results: A total of 198 patients were included in the analysis, of whom 114 (57.6%) were ≥70 years old, with a CR rate of 36.9% for patients <70 years old and 61.4% for those ≥70 years old (p = 0.001). In univariate analysis, age <70 years old, female sex, no drinking history, no smoking history and CBDCA dose were associated with non-CR. In multivariate analysis, age <70 years old, no drinking history and CBDCA dose were associated with non-CR.

Conclusion: Age <70 years old, no drinking history and CBDCA dose were identified as risk factors for CBDCA-induced nausea and vomiting.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

求助全文

约1分钟内获得全文去求助

来源期刊

Oncology 医学-肿瘤学

CiteScore

6.00

自引率

2.90%

发文量

审稿时长

6-12 weeks

期刊介绍： Although laboratory and clinical cancer research need to be closely linked, observations at the basic level often remain removed from medical applications. This journal works to accelerate the translation of experimental results into the clinic, and back again into the laboratory for further investigation. The fundamental purpose of this effort is to advance clinically-relevant knowledge of cancer, and improve the outcome of prevention, diagnosis and treatment of malignant disease. The journal publishes significant clinical studies from cancer programs around the world, along with important translational laboratory findings, mini-reviews (invited and submitted) and in-depth discussions of evolving and controversial topics in the oncology arena. A unique feature of the journal is a new section which focuses on rapid peer-review and subsequent publication of short reports of phase 1 and phase 2 clinical cancer trials, with a goal of insuring that high-quality clinical cancer research quickly enters the public domain, regardless of the trial’s ultimate conclusions regarding efficacy or toxicity.